REGENXBIO Inc. (RB0.F)
Frankfurt · EUR · Healthcare · Biotechnology
€5.85 (-0.48%) as of
Key statistics
- Market cap
- 386.18M
- Forward P/E
- -1.35
- EPS (TTM)
- -3.03
- Dividend yield
- 0.00%
- 52-week range
- 4.73 – 13.60
- Beta
- 1.13
- Revenue (TTM)
- 174.48M
- Profit margin
- -112.58%
- Volume
- 1.60k
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Rockville, MD, United States
- Employees
- 371
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.